• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Honors 54 Nephrology Nurses with DAISY Awards

    5/9/24 10:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email

    Award celebrates excellence in nursing, underscoring the kidney care provider's commitment to recognizing the indelible impact of clinicians on outstanding patient care

    DENVER, May 9, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that 54 of its nephrology nurses were honored with the DAISY Award® for Extraordinary Nurses during National Nurses Week. The award is part of The DAISY Foundation's mission to recognize nurses who provide outstanding, compassionate care in more than 6,500 health care facilities nationwide.

    DaVita Logo (PRNewsfoto/DaVita)

    "Nurses are such a significant part of the health care workforce, and they are at the heart of the care we provide at DaVita," said Tina Livaudais, chief nursing officer for DaVita. "I'm inspired by the stories of compassion, empathy and selflessness that each of our DAISY recipients embodies. This award reflects the clinical excellence they deliver to our patients every day."

    DaVita's commitment to clinical excellence is reflected in the care it offers patients during each step of their kidney care journey. The DaVita nurses who received a DAISY Award this year represent each of the dialysis treatment settings that DaVita offers:

    • 40 in-center hemodialysis nurses
    • 6 home hemodialysis and peritoneal dialysis nurses
    • 8 acute dialysis nurses who deliver care in a hospital setting

    DaVita's DAISY Award recipients were nominated by fellow employees (teammates) and patients for helping drive clinical outcomes and consistently demonstrating DaVita's Caring Behaviors, known as WE CARE: Welcome, Empathize, Connect, Actively Listen, Respect and Encourage.

    The DAISY Foundation™ was established in memory of J. Patrick Barnes by members of his family. Patrick died at the age of 33 in 1999 from complications of Idiopathic Thrombocytopenic Purpura (ITP), a little-known but not uncommon auto-immune disease. DAISY is an acronym for Diseases Attacking the Immune SYstem. The care Patrick and his family received from nurses while he was ill inspired this unique means of thanking nurses for making a profound difference in the lives of their patients and patient families.

    "When Patrick was critically ill, our family experienced first-hand the remarkable skill and care nurses provide patients every day and night," said Bonnie Barnes, FAAN, doctor of humane letters and co-founder of The DAISY Foundation. "Yet, these unsung heroes are seldom recognized for the super-human, extraordinary, compassionate work they do. The kind of work the nurses at DaVita are called on to do every day epitomizes the purpose of the DAISY Award."

    A robust nursing workforce is essential for the care of kidney disease patients. DaVita has expanded efforts to help address the critical nursing workforce shortage facing the U.S. The company's programs to energize the next generation of nursing talent to join the nursing field include:

    • A nephrology-practice specialty curriculum offered through Chamberlain University, the largest online school of nursing in the U.S.
    • A five-level career mapping model, Clinical Ladders, that provides teammates with the tools and resources needed to grow their careers.
    • Tuition reimbursement for full- and part-time teammates interested in pursuing a nursing degree.
    • The holistic Bridge to Your Dreams program that supports high-performing teammates in pursuing an associate's degree in nursing through financial assistance, uniquely designed resources and support with nursing role placement at DaVita.

    To learn more about how DaVita supports nurses throughout their careers, visit Careers.DaVita.com.

    About DaVita Inc.

    DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of March 31, 2024, DaVita served approximately 258,600 patients at 3,092 outpatient dialysis centers, of which 2,665 centers were located in the United States and 427 centers were located in 12 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

    CONTACTS

    DaVita Inc.

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-honors-54-nephrology-nurses-with-daisy-awards-302140660.html

    SOURCE DaVita

    Get the next $DVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Inc. to Participate in Fireside Chat with Wolfe Research

    DENVER, Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Conference on Monday, November 17, 2025, at 11:20 am EST. To view the live webcast, visit the Wolfe Research page here and create a free registration. About DaVita Inc.DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—fro

    11/14/25 4:16:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025

    Six new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON, Nov. 4, 2025 /PRNewswire/ -- DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights — spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more. As DaVita celebrates 25 ye

    11/4/25 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 3rd Quarter 2025 Results

    DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners." Financial and operating highlights for the quarter ended September 30, 2025: Consolidated revenues were $3.420 billion.Operating income was $506 million and adjusted operating

    10/29/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

    11/1/22 9:18:39 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Yale Phyllis R was granted 411 shares, increasing direct ownership by 3% to 13,981 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    11/17/25 6:47:50 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Schoppert Wendy Lee was granted 411 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    11/17/25 6:47:32 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Schechter Adam H was granted 411 shares, increasing direct ownership by 9% to 5,110 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    11/17/25 6:47:07 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.

    SCHEDULE 13G/A - DAVITA INC. (0000927066) (Subject)

    10/30/25 2:54:34 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by DaVita Inc.

    10-Q - DAVITA INC. (0000927066) (Filer)

    10/29/25 5:05:01 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    10/29/25 4:09:27 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 3rd Quarter 2025 Results

    DENVER, Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our expectations and keeps us on track to achieve our full-year guidance," said Javier Rodriguez, CEO of DaVita. "Our consistent focus on providing outstanding care is the key to these results, enabling us to continuously invest in improving the lives of our patients and supporting our dedicated teammates and physician partners." Financial and operating highlights for the quarter ended September 30, 2025: Consolidated revenues were $3.420 billion.Operating income was $506 million and adjusted operating

    10/29/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

    DENVER, Oct. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Wednesday, October 29, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Wednesday, October 29, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to l

    10/13/25 2:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 2nd Quarter 2025 Results

    DENVER, Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by our unwavering focus on patient care," said Javier Rodriguez, CEO of DaVita Inc. "We continued to deliver exceptional clinical outcomes for our patients, fostered a positive experience for our caregivers, and delivered on our financial commitments with disciplined execution across our businesses." Financial and operating highlights for the quarter ended June 30, 2025: Consolidated revenues were $3.380 billion.Operating income was $538 million and adjusted operating income was $551 million.Diluted earnings

    8/5/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care